Abstract: Since telomerase has been recognized as a relevant factor distinguishing cancer cells from normal cells, it has become a very promising target for anti-cancer therapy. A correlation between short telomere length and increased mortality was revealed in many studies. The telomerase expression/activity appears to be one of the most crucial factors to study to improve cancer therapy and prevention. However, this multisubunit enzymatic complex can be regulated at various levels. Thus, several strategies have been proposed to control telomerase in cancer cells such as anti-sense technology against TR and TERT, ribozymes against TERT, anti-estrogens, progesterone, vitamin D, retinoic acid, quadruplex stabilizers, telomere and telomerase targeting agents, modulation of interaction with other proteins involved in the regulation of telomerase and telomeres, etc. However, the transcription control of key telomerase subunits seems to play the crucial role in whole complexes activity and cancer cells immortality. Thus, the research of telomerase regulation can bring significant insight into the knowledge concerning stem cells metabolism but also ageing. This review summarizes the current state of knowledge of numerous telomerase regulation mechanisms at the transcription level in human that might become attractive anti-cancer therapy targets.
Introduction
The Nobel Prize in Physiology or Medicine awarded in 2009 to Elizabeth H. Blackburn, Carol W. Greider, Jack W. Szostak for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase highlighted the important role of telomerase and telomeres in genome stability, immortality, and aging. Regulation of telomerase activity and expression occurs at many levels, including transcription, alternative splicing, chaperone-mediated folding, phosphorylation, nuclear translocation of each subunit, assembly of the telomerase complex, and its accessibility to telomeres (Cong et al. 2002; Wojtyla et al. 2011; Chan and Chang 2010) . However, as reported so far, increased telomerase activity is always correlated with upregulation of the telomerase reverse transcriptase (TERT) gene and an increased level of TERT mRNA. Telomerase substrates, telomeres, are guanine-rich repeated sequences located at the ends of chromosomes. The loss of telomeric repeats after each cell division may function as a biological clock limiting the cell proliferation ability (Hayflick limit; Hayflick and Moorhead 1961; Fig. 1) . Telomerase, the RNA-dependent DNA polymerase, synthesizes telomeric DNA and thus enables cancer cells with an unlimited proliferative potential. The enzyme activity is observed in most malignant cells but undetectable in most normal cells. Only a small number of cells, including lymphocytes that were stimulated to divide, intestinal epithelium, esophageal epithelium, cycling endometrium, basal keratinocytes, cervical epithelium, and hematopoietic stem cells, show telomerase activity. In some cases, human tissues that are telomerase-negative, become telomerase-positive when growth is stimulated, as in the cases of lymphocytes and uroepithelial cells. Thus, the enzyme and its altered activity, characteristic for cancer cells, is an attractive molecular target for anti-cancer therapy.
Numerous proto-oncogenes and tumor suppressor genes are engaged in telomerase control and the complexity of this mechanism is studied in the context of tumor development as well as aging. Due to the significant role of telomerase in those processes, it is of great interest to identify the enzyme expression/activity regulators (possibly within tumor suppressors or oncogenes). Moreover, since telomerase expression is characteristic for stem cells but not for differentiated cells, the study of regulatory pathways that control telomerase expression may be critical for maintenance of the stem cell state. Additionally, since in numerous studies a correlation between short telomere length and increased mortality was revealed, the telomerase expression/activity appears to be one of the most crucial factors to study to improve the anticancer therapy and prevention.
Telomerase
Human telomerase as a multisubunit ribonucleoprotein (RNP) is the reverse transcriptase (RT) family member, and the RT-like domain is composed of 7 conservative motifs and telomerase-specific T motif (Meyerson et al. 1997; Nakamura et al. 1997) . The catalytic telomerase protein subunit (TERT) is encoded by a gene located on chromosome 5p15.33 (Meyerson et al. 1997 ).
The TERT promoter was shown to contain no TATA box or TATA-like sequence, and the presence of binding sites for several transcription factors (i.e., c-Myc/Mad/Max, Sp1, USF, AP2, AP4, and NF1), hormone response elements and 2 Eboxes (Cong et al. 1999; Takakura et al. 1999 ) was revealed. The RNA component (TR) of telomerase (3q21-q28) provides the template for telomeric repeat synthesis. A number of RNA binding proteins, such as hGAR, dyskerin, hNOP10, hNHP2, hStau, L22, hnRNP C1/C1, La, and TERT, interact with TR and are involved in TR stability, maturation, accumulation, and functional assembly of the telomerase ribonucleoprotein complex (Mitchell et al. 1999a (Mitchell et al. , 1999b Le et al. 2000; Pogacić et al. 2000; Ford et al. 2000 Ford et al. , 2001 Dez et al. 2001; Chan and Chang 2010) .
Transactivation of telomerase, essential for cells immortalization, is supposed to be one of the reasons for cancer transformation. There are many studies in which exogenous factors influencing TERT, e.g., several viruses are known to be involved in tumorigenesis of infected tissues, have already been widely discussed (Horikawa and Barrett 2003; Bellon and Nicot 2008; Strååt et al. 2009; Liu et al. 2010 ). Thus, due to complexity of the telomerase regulation, there is on the one hand a lot of work yet to be done, but on the other hand, there are a lot of potential ways to target and thus stop the immortality enzyme.
Transcription induction
Myc/Mad/Max pathway c-Myc is a basic helix-loop-helix transcription factor. Involvement of this protein in telomerase regulation was widely investigated, and its role in TERT gene expression activation was confirmed in many studies (Wang et al. 1998a; Wu et al. 1999; Fujiki et al. 2010) . It was indicated that both pontin and reptin (ATPases associated with various cellular activities) interact with TERT and dyskerin and are essential for assembly of a core telomerase complex, including TERT, TR, and dyskerin (Venteicher et al. 2008) . Because c-Myc binding motifs on the TERT promoter are required for reptin depletion-mediated reduction of the promoter activity, consequently, reptin and c-Myc were shown to possibly form a positive feedback loop to regulate their expression and functional activities . In the studies on human megakaryocytic-erythroid cell line (JAS-R), it was found that after exposure to EPO, c-Myc protein expression was induced and that this induction was followed by TERT protein increase (Akiyama et al. 2010) .
Recently several endogenous compounds were found to exhibit anti-tumor activity. One of them is butein (3,4,2′,4′-tetrahydroxychalcone), a polyphenolic compound causing down-regulation of telomerase through suppression of TERT gene expression. Moreover, it was demonstrated that this suppression is c-MYC dependent, because butein prevents c-MYC binding to the TERT promoter (Moon et al. 2009b ). Another compound, PTX2, the most toxic compound from the group of pectenotoxins (found in marine sponges and shellfish), was shown to down-regulate telomerase activity through the suppression of TERT gene expression at the transcriptional level (Lee et al. 1989) . In later studies it was shown that PTX2-dependent attenuation of TERT expression was mediated through suppression of c-Myc-and Sp1-binding on the regulatory regions of TERT (Kim et al. 2008) . Both factors influenced telomerase also on the posttranscriptional level by attenuation of Akt phosphorylation, thereby reducing the phosphorylation and nuclear translocation of hTERT (Kim et al. 2008; Moon et al. 2009b ). Comparing telomerase-positive and alternative lengthening of telomeres (ALT) cells it was found that c-Myc activity was lower in ALT cells but there was no difference in the gene expression. It was further demonstrated that in ALT cells the level of TCEAL7 (transcription elongation factor A (SII)-like 7), competitive inhibitor of c-Myc, was elevated suggesting that this factor might be indirectly involved in telomerase regulation by regulating the activity of c-Myc in telomerase-positive and negative cells (Lafferty-Whyte et al. 2010) . In the study of colon cancer cells, it was indicated that shRNA directed against c-Myc decreased protein level and significantly inhibited the growth rate of cancer cells. Moreover, c-Myc-shRNA was shown to significantly reduce telomere length and telomerase activity in siRNA-transfected colon cancer cells in a dose-dependent manner (Hao et al. 2008) . This study supported the notion that factors involved in telomerase regulation could be good targets for anti-cancer therapies (Cesare and Reddel 2010; Henson and Reddel 2010) .
NF-kB
Telomerase activity is essential for replicative longevity of vascular cells. It was found that TERT was upregulated in smooth muscle cells (SMCs) during vascular injury, involving activation of the nuclear factor kB (NF-kB) pathway. Moreover, it was indicated that activation of c-Myc signaling was involved in this process. Inhibition of NF-kB in both intimal SMCs and the injured artery attenuated TERT transcriptional activity through reduction of c-Myc expression. These results support a model in which vascular injury induces de novo expression of TERT in intimal SMCs via activation of nuclear factor and upregulation of c-Myc (Bu et al. 2010) . Other authors demonstrated that telomerase is activated during atherosclerosis and identified a NF-kB response element in the TERT promoter. They indicated that inflammatory stimuli activated telomerase in macrophages by inducing the expression of TERT. Thus, induction of TERT expression during atherosclerosis was suggested to prevent macrophage senescence (Gizard et al. 2011) .
NFAT
Lymphocytes exhibit telomerase activity in response to stimulation (Buchkovich and Greider 1996) . Nuclear factor of activated T cells (NFAT) is a transcription factor that plays an important role in lymphocyte activation. It stimulates the TERT promoter mainly through a consensus binding site localized in the core promoter. SP1-binding sites flank the putative NFAT-binding site, and it was demonstrated that both factors cooperate in the TERT activation process. Moreover, in cancer cell line inhibition of NFAT1 expression decreased TERT mRNA level indicating role of NFAT1 in transcriptional regulation of telomerase (Chebel et al. 2009 ).
Ets
The Ets TFs (transcription factors) comprise a family of more than 30 members that share the characteristic structure known as the erythroblast transformation specific (ETS) domain (Dwyer and Liu 2010) . The Ets TFs have been reported to participate in the regulation of telomerase (Maida et al. 2002; Goueli and Janknecht 2003; Xiao et al. 2003) . Moreover, it was also reported that Ets2 is required for TERT gene expression and breast cancer cell proliferation (Dwyer et al. 2007; Xu et al. 2008a) . As demonstrated, silencing Ets2 resulted in a decrease of TERT gene expression and increase in human breast cancer cell death while reconstitution with recombinant TERT inverted that effect. Moreover, Ets2 was shown to form a complex with c-Myc as demonstrated by co-immunoprecipitation and glutathione S-transferase pulldown assays (Xu et al. 2008a) . Immunological depletion of Ets2, or mutation of the EtsA DNA motif, disables c-Myc binding to the E-box, whereas removal of c-Myc or mutation of the E-box also compromises Ets2 binding to EtsA. Thus, TERT gene expression was shown to be maintained by a mechanism involving Ets2 interactions with the c-Myc transcription factor and the TERT gene promoter that consequently affected TERT gene expression and breast cancer cell proliferation (Xu et al. 2008b ).
Her2/Neu, Ras, and Raf pathway As already shown, several Ets transcription factors are involved in regulation of TERT gene expression, both directly and indirectly through the proto-oncogenes (Dwyer et al. 2007) . Another member of ETS TFs family is supposed to mediate telomerase activation in telomerase-negative fibroblasts stimulated by oncogenes Her2/Neu, Ras, and Raf (Dwyer et al. 2007 ). Both, Her2 and ER81, have been suggested to cause a synergistic increase in the transcriptional activation of TERT in breast cancer patients, and it was suggested that the activation of TERT could be mainly mediated by transcriptional activation of ER81 (Vageli et al. 2009 ). However, it was suggested that TERT gene expression could also be enforced by activating mutations of oncogenes such as HER2/Neu, Ras, and Raf. Thus, 2 different mechanisms, the inactivation of tumor suppressors and (or) the activation of oncoproteins, was suggested to account for immortaliza-tion of tumor cells through the induction of TERT transcription. Interestingly, breast cancer cells showing overexpression of Her2/Neu oncoprotein (UACC893, SKBR3, T47D) were reported to show higher telomerase activity than cells deprived of Her2/Neu expression (Goueli and Janknecht 2004) . In telomerase-negative, nonimmortalized BJ foreskin fibroblasts, the overexpression of Her2/Neu alone was shown not to influence telomerase activity while the additive effect of HER2/Neu, Ras, and Raf affected ER81 to enhance endogenous TERT gene transcription and telomerase activity in these cells (Goueli and Janknecht 2004) . Thus, the contribution of HER2/Neu, Ras, and Raf to tumor formation by inducing TERT expression in nonimmortalized cells via the transcription factor ER81 was demonstrated. As reported, HER2/Neu, Ras, and Raf, stimulated TERT promoter activity via the Ets transcription factor ER81 and ERK mitogen-activated protein (MAP) kinases. Moreover, expression of dominant-negative ER81 or inhibition of HER2/Neu was reported to significantly attenuate telomerase activity in HER2/Neu-overexpressing SKBR3 breast cancer cells (Goueli and Janknecht 2004) . It was also reported that the epidermal growth factor receptor collaborated with Ets2 to enhance TERT expression in immortalized, TERT-positive cells but not in nonimmortalized cells that are representative of normal somatic cells prior to oncogenic transformation (Maida et al. 2002) . Thus, 3 prominent human oncoproteins (HER2/Neu, Ras, and Raf) were shown to be able to transform a telomerase-negative cell to a telomerase-positive cell by activating ER81 and consequently upregulating TERT expression, as occurs in 90% of all human tumor cells via the ERK MAP kinase pathway and ER81 (Kim et al. 1994; Meyerson et al. 1997; Hiyama and Hiyama 2002) . Accordingly, TERT expression was shown to increase in HER2/ Neu-positive breast tumors and breast tumor cell lines relative to their HER2/Neu-negative counterparts. Thus, it was concluded that those oncoproteins, HER2/Neu, Ras, and Raf, might facilitate tumor formation by inducing TERT expression in nonimmortalized cells via the transcription factor ER81, which revealed another target for combined anti-cancer therapy.
Steroid hormones
Estrogen receptors (ERs) ERa and ERb are ligand-dependent transcription factors capable of direct interaction between the hormone-receptor complex and estrogen responsive elements (EREs) (Beato and Sánchez-Pacheco 1996) . It was revealed that the 5′ flanking region of the TERT promoter contained a putative ERE at position -949 to -935 upstream of ATG (Cong et al. 1999; Kyo et al. 1999; Bayne and Liu 2005; Boggess et al. 2006; Martínez-Campa et al. 2008) . In normal, telomerase-negative ovary epithelial cells, after treatment with 17b-estradiol (E2), transient expression of ERa was observed that resulted in increased TERT promoter activity. In contrast, expression of ERb was shown not to affect telomerase expression. As reported, ERa-dependent activation was reduced by ERE mutation, confirming a significant role of this element in telomerase regulation (Misiti et al. 2000) . In prostate tumorgenesis studies the direct role of ERs in TERT expression control was confirmed. Telomerase-negative normal prostate epithelial cells and fresh explants from lesions, representing different stages of disease, were shown to significantly increase TERT promoter activity upon E2 stimulation. Moreover, results from ChIP assays showed recruitment of ERa and ERb onto the TERT promoter, indicating that both are important in the genes regulation (Nanni et al. 2002) . Recently, in the human umbilical vein endothelial cells (HUVEC) study it was shown that E2-dependent activation of telomerase required endothelial nitric oxide synthase (eNOS) activity (Grasselli et al. 2008) . Since the promoter region of the catalytic subunit of the telomerase enzyme, TERT, was shown to contain putative EREs, it was postulated that ER-mediated induction of telomerase activity might play an important role in carcinogenesis. Those results were confirmed in other studies that revealed both TERT gene transcription and telomerase activity induction by E2 in the ER-positive cell lines, but not in the ER-negative cell lines Misiti et al. 2000; Wang et al. 2000; Boggess et al. 2006) . Moreover, it was also demonstrated that transfection of ERa into ER-negative cell lines restored E2-induced TERT gene transcription and telomerase activity. Thus, a possible mechanism for telomerase induction that may facilitate the malignant transformation of hormone-dependent endometrial cells was suggested. Additionally, upregulation of telomerase activity in ER-positive MCF-7 cells was also reported after treatment with 17b-estradiol (E2) that was accompanied by induction of TERT mRNA (Kyo et al.1999) and similarly in human umbilical vein endothelial cells (Grasselli et al. 2008 ) and human mesenchymal stem cells (hMSCs) (Cha et al. 2008) , indicating the activation of TERT expression and telomerase activity by E2 (ERa-dependent but not ERb in hMSCs cells). It was also demonstrated that estrogen activated c-Myc expression in MCF-7 cells and that E-boxes in the TERT promoter that bind cMyc/Max play additional roles in estrogen-induced transactivation of TERT. Interestingly, lower telomerase activity was found among tumors that did not express ERb that suggested the absence of expression of ERb is associated with low levels of telomerase activity (Murillo-Ortiz et al. 2006) . Other authors revealed that down-regulation by siRNA of ERa, but not ERb, inhibited estrogen-stimulated telomerase function showing the mechanism for androgen therapy in bone marrow failure due to potential contribution of androgens to regulation of telomerase expression and activity mainly by aromatization and through ERa (Calado et al. 2009 ). Thus, androgens were shown to stimulate telomerase activity and TERT gene expression in normal stimulated lymphocytes while estradiol also stimulates telomerase activity in human primary lymphocytes (Calado et al. 2009 ). Additionally, dexamethasone (Dex) was also shown to reduce telomerase activity through the inhibition of TERT expression before the induction of apoptosis (Akiyama et al. 2002) , while hydrocortisone did not influence telomerase activity in lymphocytes (Calado et al. 2009 ). Estrogens were then shown to activate telomerase via direct and indirect effects on the TERT promoter and suggested hormonal control of telomerase activity, cellular senescence, and aging as well as estrogen-induced carcinogenesis ). Generally, due to different mechanisms of telomerase regulation demonstrated in various cells, potential physiologic implications for telomere stability during the human reproductive period and for a relationship between sex hormones and cancer susceptibility must be considered.
HIF
Expression of TERT increases during hypoxia exposure in different cell lines (Seimiya et al. 1999; Minamino et al. 2001; Lou et al. 2007 ). It was reported that reduced levels of oxygen led to induction of TERT phosphorylation and increased telomerase activity with lifespan extension of cells in vitro (Yatabe et al. 2004) . The level of telomerase activity in hypoxia is significantly higher (4-to 5-fold) than in laboratory conditions, while the quantity of TERT protein is comparable (Minamino et al. 2001) . It was also demonstrated in placental JAR and JEG-3 cell studies that expression of HIF1a protein (hypoxia inducible factor, type1a) strongly correlated with TERT expression, indicating that HIF-1a activates telomerase through direct interaction with TERT regulatory regions. In an electrophoretic mobility shift assay, the presence of 2 putative HIF-1 binding sites in the TERT promoter (between -165 and -158 and between +44 and +51) were found essential for telomerase regulation ). On the other hand, in colonic cancer epithelial cell line (HCT116) studies an opposite function of HIF-1a was indicated. Authors showed that HIF-1a counteracted with c-Myc activity and down-regulated expression of c-Myc target genes, including TERT (Koshiji et al. 2004) . A paralog of HIF-1a, the HIF-2a, also seems to play a specific, cell-dependent role in telomerase regulation. Renal cell carcinoma cells, A498, with constitutive expression of HIF-2a, revealed increased TERT expression in hypoxic conditions, while depletion of HIF-2a attenuated this effect. In contrary, in glioma cell lines (U251, U373, and U563), HIF-2a was shown to inhibit TERT promoter activity. The mechanism of this opposing effect of HIF-2a on TERT promoter remains elusive (Lou et al. 2007 ); however, hypoxia appeared to be another factor contributing to telomerase activity/expression control.
Telomerase transcription repression
The TERT gene is expressed in most cancer cells, and its analysis provided evidence for the existence of negative and positive Ets regulatory sites and suggested a complex interplay between Ets/Id family members and c-Myc that might be an important determinant of the diversity of telomerase activity in cancer cells (Xiao et al. 2003) . These findings revealed an endogenous, repressive mechanism that actively functions in telomerase/TERT-negative normal cells and becomes defective during carcinogenic processes, e.g., by an inactivation of the telomerase repressor gene on chromosome 3 (Horikawa et al. 2002) . Recently the role of chromosome 5 in telomerase regulation was also investigated, indicating its involvement in transcriptional suppression of TERT (Qi et al. 2010) . TERT transcription is repressed in normal somatic cells (Ducrest et al. 2002) due to activity of Mad1, p53, and the Wilms' tumor suppressor gene product 1 (WT1) (Poole et al. 2001) . Another tumor suppressor, menin, has also been shown to associate with the TERT promoter and knocking down its expression in BJ cells (Lin and Elledge 2003) . Thus, it was concluded that inactivating mutations in tumor suppressors might lead to the derepression of the TERT gene and consequently to telomerase activity increase and immortalization. Genetic screening to identify potential transcriptional TERT repressors using enhanced retroviral mutagens (ERM ) revealed numerous candidates (Lin and Elledge 2003) .
In the study of TERT gene structure, a 400 bp silencer of the TERT promoter between -776 and -378 upstream of the proximal core promoter was identified (Fujimoto et al. 2000) . Homology studies revealed multiple binding motifs for myeloid-specific zinc finger protein 2 (MZF-2) within this region. Interestingly, mutation introduced in these sites resulted in significant activation of TERT transcription. It was then demonstrated that MZF-2 proteins specifically bound to these sites while overexpression of MZF-2 in cells led to down-regulation of TERT transcription as well as telomerase activity. Thus, the 400 bp region upstream of the TERT core promoter was identified as a negative regulatory region and that MZF-2 may be an effector of negative regulation of TERT (Fujimoto et al. 2000; Yang et al. 2010 ). Thus, it was also suggested that multiple tumor suppressor/ oncogene pathways coordinately repressed TERT expression and implied that telomerase was reactivated in human tumors through oncogenic mutations. Interestingly, the contribution of the mitogen-activated protein kinase kinase 1 (MEKK1) / c-Jun-NH(2)-kinase (JNK) pathway to the TR subunit expression was demonstrated (Bilsland et al. 2006) . As reported, mutations in the TR promoter Sp1/Sp3 binding sites attenuated SP600125-mediated (the JNK inhibitor) promoter induction, whereas coexpression of MEKK1 with Sp3 enhanced TR promoter repression. It was also revealed that Akt was not involved in the signaling cascade for telomerase regulation in ovarian surface epithelial cells. However, it was shown that JNK induced telomerase activity, that inhibition of JNK by JIP abrogated telomerase activity, and that JNK expression activated transcription of a reporter gene fused to the TERT promoter sequence. Consequently, JNK was shown as a key regulator of telomerase activity that may provide new perspectives on tumorigenesis that could be exploited for novel therapeutic strategies (Alfonso-De Matte et al. 2002) . Beyne-Rauzy et al. (2005) revealed that tumor necrosis factor-alpha (TNFa) induced in the leukemic KG1 cells a senescence state due to decreased TERT activity followed by prolonged growth arrest, increased b-galactosidase activity, telomere shortening, and major chromosomal instability. It was demonstrated that TNFa induced sphingomyelin hydrolysis, ceramide production, and c-Jun N-terminal kinase (JNK) activation in KG1 cells, resulting in TERT gene inhibition, which gives another possible pathway to target in anticancer strategy.
Menin/Mad1 pathway
Menin, which is a tumor suppressor and a gene product of MEN1, has been reported to play a critical role in the telomerase repression. While menin appears to have some inhibitory effects on the TERT promoter, possibly via the sequence-independent binding to the promoter, other authors suggested indirect contribution of menin to the telomerase activity regulation in normal and cancer cells (Suphapeetiporn et al. 2002) . In another study, the presence of a binding site for menin in TERT promoter was not shown and no evidence to indicate menin involvement in TERT repression was found (Hashimoto et al. 2008) .
However, TERT mRNA levels measured by RT-PCR was decreased in cells overexpressing menin, Rak, SIP1, and Mad1 suggesting their role in telomerase repression. Moreover, when siRNA was used to reduce the expression levels of these individual candidates (Rak, menin, Mad1, and Brit1) in U2OS cells (osteosarcoma-derived cell line) that do not normally express TERT, dramatic and rapid TERT mRNA increase was observed (Lin and Elledge 2003) .
Mad1 was shown to inhibit the proliferation of human bladder cancer cells by inhibiting TERT transcription and telomerase activity suggesting that Mad1 could be a potentially useful candidate for inhibition of this type of cancer cell (Zou et al. 2006) . In numerous studies it was implicated that Mad1 could be a negative regulator of telomerase expression (Günes et al. 2000; Oh et al. 2001; Xu et al. 2001) . Mad1 has been shown to bind the TERT promoter, at the same sites as c-Myc, and negatively regulate its transcription. Mad1-mediated repression of the TERT promoter could be counteracted by ectopic expression of c-Myc (Oh et al. 2001) . However, it is not clear how Mad1 competes with c-Myc for the same recognition sequence in the TERT core promoter region (Casillas et al. 2003) . As reported, cells with a high replicative potential (and telomerase activity), such as undifferentiated BeWo cells, are characterized by high levels of c-Myc, while Mad1 expression is generally minimal in these cells. Interestingly, in human anaplastic thyroid carcinoma (ATC) cell lines, different, contradictive observations were made showing TGF-b1 decreasing the telomerase activity in HTh 74 and KTC-1 cells, while in C 643 and HTh 7 an increased activity was observed (Lindkvist et al. 2005) , possibly reflecting deregulation of TGF-b1 signaling in more malignant cells. Also a crucial role of TGF-b1 and SIP1 (a transcriptional target of the TGF-b pathway) in mediating the TERT repression was demonstrated (Rama et al. 2003; Lin and Elledge 2003) .
USF
Another protein involved in telomerase regulation is upstream stimulatory factor (USF). It binds to both E-boxes in TERT gene promoter independently of Myc/Max in tumor cells (Horikawa et al. 2002; Yago et al. 2002) . It is supposed that it associates with TERT gene promoter primarily as USF1/USF2 heterodimer (Goueli and Janknecht 2003) . Moreover, the same authors showed that USF1/2 bind both E-boxes, regardless of cellular immortalization status, but is transcriptionally active only in immortalized cells. Transcriptional activity might correlate with USF phosphorylation by p38-MAP kinases and recruiting histone acetyltransferase p300 to the TERT promoter where it facilitates transcription (Goueli and Janknecht 2003) . By comparing oral cancer tissues with their normal counterparts, it was indicated that in general USF1 and USF2 were expressed at lower levels in cancers. Hence, it is supposed that USF may play a negative regulatory role in TERT expression and telomerase activity in the normal tissues and that this effect is lost in cancer cells . Moreover, USF1 and USF2 are able to abrogate the upregulation of TERT promoter by c-Myc through direct binding at the E-box site of TERT gene promoter Jiang et al. 2010 ).
BRCA1
The BRCA1 gene encodes nuclear phosphoprotein that plays a role in maintaining genomic stability and acts as a tumor suppressor. It was found to interact with c-Myc by association of helix-loop-helix region of c-Myc, a motif involved in c-Myc-Max dimerization. However, BRCA1 does not bind to Max (Wang et al. 1998b) . It was indicated that overexpression of the BRCA1 gene inhibits TERT expression and telomerase enzymatic activity in various cell types via the inhibition of c-Myc-mediated transactivation of the TERT promoter (Zhou and Liu 2003; Xiong et al. 2003) . Furthermore, it is suggested that BRCA1 and Nmi (N-Myc and cMyc interacting protein) can form a complex with c-Myc in vitro and in vivo. This tricomplex results in inhibition of cMyc-induced TERT promoter activity in breast cancer cells . BRCA1 is also involved in telomere shortening independently of telomerase (Xiong et al. 2003; Ballal et al. 2009 ). BRCA1 interacts with TRF1 and TRF2 and it is suggested that BRCA1 regulates the length of the 3′ G-rich overhang by being recruited to the telomere in a Rad50-dependent manner (Ballal et al. 2009 ).
PPARg
During studies of human peripheral blood mononuclear cells (PBMCs), it was indicated that in the presence of activated C k receptor the TERT, c-Myc, and peroxisome proliferator-activated receptor g (PPARg) mRNAs levels were decreased (Sikand et al. 2006) . Moreover, authors suggested that PPARg could act as a negative regulator of TERT transcription and indicated that down-regulation of telomerase in this mechanism involved protein kinase C (PKC) inhibition (Sikand et al. 2006) . In several studies on vascular smooth muscle cells (VSMCs), a crucial role of PPARg in inhibition of mitogen-activated telomerase activity was demonstrated (Cao et al. 2002; Minamino and Komuro 2003) . TERT gene promoter lacks any putative PPARg response elements, so it is plausible that the mechanism of telomerase regulation by PPARg is indirect. Thus, it was suggested that PPARg inhibited Ets-1-dependent transactivation of the TERT promoter (Ogawa et al. 2006) . Another member ofthe nuclear hormone receptor superfamily PPARa was also shown to be involved in telomerase down-regulation in VSMCs. Authors proposed a model in which PPARa recruited pocket proteins p107 and p130 via p16-dependent pathway to the TERT promoter and altered the ability of E2F-1 binding site to activate the TERT transcription (Gizard et al. 2008) . Moreover, PPARg ligands were shown to inhibit telomerase activity and TERT expression through modulation of the Myc/Mad/Max network in colon cancer CaCo-2cells (Toaldo et al. 2010 ).
WT1
Wilm's tumor 1 suppressor gene product (WT1) is known to bind to a specific recognition sequence on the TERT promoter and to suppress telomerase activity Cong et al. 2002) . A member of the WT1 gene family, transcription factor early growth response 1 (Egr-1 ), was shown to mediate down-regulation of telomerase in cervical cancer cells demonstrating a negative correlation of Egr-1 and TERT mRNA levels. In the studies of cervical cancer cells CaSki and SiHa, Egr-1 was shown to decrease protein expression and mRNA levels of TERT while a specific binding site for this factor was found in the telomerase promoter region (Akutagawa et al. 2008).
p53/p73
It was demonstrated that p53 repressed telomerase activity through down-regulation of TERT transcription and that interaction of p53 with Sp1 or other transcription factors may be involved in this regulation Toh et al. 2005) . It was found that ectoptic expression of p73b, in contrast to p73a or p53, in p53 null H1299 cells did not lead to suppression of TERT transcription (Toh et al. 2005) . However co-expression of p73a or p73b together with p53 abolished p53-mediated TERT suppression. This phenomenon was found to be dependent on the DNA binding ability of p73. In addition, knockdown of HDM2 (the p53 E3 ubiquitin ligase human double minute 2 protein) in MCF7 cells, which express moderately high levels of p73 and p53, resulted in a reduction of endogenous TERT levels. Finally, knockdown of p73 in MCF7 cells resulted in increased p53 protein levels and a concomitant decrease in TERT levels. Together, a plausible way was indicated by which p73, through HDM2, can oppose p53 tumor suppressor function, thereby possibly contributing to tumorigenesis (Toh et al. 2005) . In the studies on MCF7 and LNCaP cancer cells it was revealed that cyclindependent kinase inhibitor p21 is essential for p53-mediated telomerase repression. Moreover, the same authors suggested that histone deacetylase activity was also involved in this process and proposed a pathway of telomerase down-regulation involving p53/p21/Rb/E2F (Shats et al. 2004) . A significant role of the E2F binding site and pocket protein family members (pRb, p107, and p130) in TERT repression was shown. It was also demonstrated that HDAC (E2F-pocket protein-histone deacetylase) recruited by the pocket protein-E2F complex is critical for TERT repression in normal human fibroblasts (Won et al. 2004) .
The latest studies concerning p53 contribution to telomerase regulation revealed that ectopic expression of TERT in spontaneously immortalized human fetal fibroblast (HFFS) cells, which are telomerase-and p53-positive, led to increased cell proliferation and transformation, as well as a resistance to DNA damage response and inactivation of p53 function due to the TERT-bFGF (basic fibroblast growth factor) axis activity (Jin et al. 2010 ). Furthermore, it was observed that the loss of TERT or bFGF markedly increased p53 activity and DNA-damage sensitivity in HFFS, HeLa, and U87MG cells. The contribution of p53 to telomerase regulation was also shown by Brandl et al. (2010) who demonstrated a novel TERT-bFGF axis accelerating the inactivation of p53 and consequent increase of resistance to DNA-damage response that is, however, independent of alteration in telomere length.
p73
The p73 protein, a structural and functional homologue of p53 encoded by the TP73 gene, was also suggested to contribute to cell cycle regulation, apoptosis, and TERT promoter repression (Jost et al. 1997; Kaghad et al. 1997 ). There are 2 main groups of this genes' expression products that come from alternative splicing or different gene promoter activation, at least 6 proapoptotic TAp73 isoforms (a, b, g, d, 3, and z) that act p53-like and Dp73 that lacks the transactivation domain that can act Das a p53 and p73 antagonist (Stiewe et al. 2002) . In studies of p53-null H1299 lung carcinoma cells, it was revealed that transient expression of a and b isoforms repressed the TERT promoter in a dose-dependent manner while g and d isoforms showed no dose-dependent inhibitory effect (Racek et al. 2005) . In further studies of p73, it was suggested that telomerase inhibition was the result of Sp1 transactivation of the TERT promoter via direct Sp1 binding (Beitzinger et al. 2006) . The mechanism of DNp73 is more complicated, and seems to be cell-or tissuespecific. In H1299 cells, binding of Rb to the E2F site was reduced by DNp73 that occurred in transcriptional activation of TERT. Furthermore, DNp73 activated TERT expression in telomerase-negative cells such as U2OS or primary human fibroblasts (Beitzinger et al. 2006 ).
NFX1-91
During the studies of human foreskin keratinocytes (HFKs) immortalized by HPV 16 oncoprotein E6, a nuclear factor NFX1-91 involved in telomerase repression was found (Gewin et al. 2004) . It was shown to bind the X-box element of MHC class II genes (Song et al. 1994 ). In the TERT proximal promoter, an X-box-like sequence was found overlapping the proximal E-box, and NFX1-91 was shown to function as a transcriptional repressor of the TERT gene in studied cells (Gewin et al. 2004) . Authors proposed that NFX1-91 through binding with the E-box on the TERT promoter could recruit mSin3A-HDAC complexes, and consequently, by maintaining deacetylated chromatin at the promoter region, block the TERT transcription (Xu et al. 2008b ).
Interferon
After exposure to interferon-g (INF-g) , down-regulation of telomerase activity and TERT mRNA level was observed in HeLa and HT-3 cells (Lee et al. 2003) . Authors revealed that although interferon regulatory factor-1 (IRF-1) did not bind directly to the TERT promoter, it played a crucial role in telomerase down-regulation (Lee et al. 2003) . In another study of telomerase regulation by INF-g/IRF-1, it was revealed that p27, a cyclin-dependent kinase inhibitor family member, might be involved in telomerase regulation, but details of this mechanism are not completely understood yet (Lee et al. 2005) . Interferon-inducible IFI16 protein was shown to contribute to cellular senescence in normal human prostate cells and human diploid fibroblasts (HDFs) (Xin et al. 2003 (Xin et al. , 2004 Choubey et al. 2008) . It was indicated that expression of IFI16 protein is inversely correlated with TERT expression in HeLa cells, because knockdown of IFI16 expression resulted in an increase in TERT protein levels. Moreover, increased levels of IFI16 protein in human normal cells inhibited TERT expression, in part, by inhibiting c-Mycstimulated transcription of the TERT gene (Song et al. 2010 ).
Epigenetics -methylation
Methylation-mediated control of gene expression is most often associated with gene silencing that may result from randomly dispersed or region-specific CpG methylation (Jones and Laird 1999) . Since post-transcriptional (alternative splicing) and epigenetic (promoter methylation) mechanisms affecting expression of the TERT gene have been reported as negative regulators of telomerase activity, a lot of studies have been performed in this field.
Analysis of the TERT gene regulatory region revealed the presence of a CpG island and a high overall GC content (Cong et al. 1999; Horikawa et al. 1999; Takakura et al. 1999; Wick et al. 1999; Guilleret and Benhattar 2004) . This feature, combined with the presence of binding sites for methylation-sensitive transcription factors within the TERT core promoter, suggested a possible role for methylation in the regulation of TERT gene expression (Poole et al. 2001) . As demonstrated, several cancer cell lines, known to express TERT, possess hypermethylated TERT promoter regions (Devereux et al. 1999; Dessain et al. 2000) suggesting a role for methylation in the blocking of negatively acting transcription factors. Similarly, normal somatic cells that do not express the TERT gene are commonly characterized as having unmethylated or hypomethylated TERT promoter regions (Devereux et al. 1999; Dessain et al. 2000) . It was also shown that methylation of the TERT promoter is necessary for its transcription and that CCCTC-binding factor (CTCF) can repress TERT transcription by binding to the first exon (Renaud et al. 2007 ). However, the CTCF binds the exon only when unmethylated. Treatment of telomerase-positive cells with 5-azadC led to a strong demethylation of the TERT 5′-regulatory region, reactivation of CTCF binding, and down-regulation of TERT. Although complete TERT promoter methylation was associated with full transcriptional repression, detailed mapping showed that in telomerase-positive cells, not all the CpG sites were methylated, especially in the promoter region. Thus, it was concluded that TERT methylation prevented binding of the CTCF repressor, but partial hypomethylation of the core promoter was necessary for TERT expression.
In several clinical studies it was revealed that TERT expression was statistically significantly higher in ovarian and cervical cancer tissue in comparison with normal tissue (Widschwendter et al. 2004) . While methylation of TERT in cervical cancer was significantly more frequent in comparison with normal cervical tissue, the difference between ovarian cancer and normal ovarian tissue was not significant. No correlation was detected between hypermethylation of TERT and TERT mRNA expression. Both ovarian cancer and normal ovary showed an increase in TERT methylation with increasing age (Widschwendter et al. 2004) . TERT expression was not correlated with prognosis, whereas cervical and ovarian cancer patients with unmethylated TERT had significantly better overall survival. Interestingly, patients with Bcell chronic lymphocytic leukemia exhibiting high telomerase activity showed significantly less methylation of the TERT promoter core domain than patients with low enzyme activity. In addition, telomerase activity was significantly associated with telomere length and overall survival (Bechter et al. 2002) . There is a clear difference in the frequency of TERT expression and methylation within tumor and non-tumor tissues. Thus, it was concluded that methylation status and telomerase expression might be useful for the diagnosis of gastric cancer and might have an impact on the anti-telomerase strategy for cancer therapy (Gigek et al. 2009 ) but might also be used as a predictive marker for increased Barrett's associated oesophageal adenocarcinoma risk (Clément et al. 2006) .
Since increased expression of TERT is related to hypermethylation of TERT in some cancer cell lines and disconcordant with hypermethylation of the p16 gene, the methylationdependent TERT expression regulation has implications for the use of demethylating agents as adjuvant to conventional chemotherapy in the treatment of pancreatic carcinoma (Nomoto et al. 2002; Kumari et al. 2009 ). At least in some tumor entities, TERT methylation is a function of age and is associated with a poorer outcome, irrespective of TERT expression. While dramatic changes in TERT promoter methylation between normal and transformed cells as well as during the senescence or differentiation process (Shin et al. 2003) support the validity of methylation-mediated control, further work in this area will be necessary to elucidate specific mechanisms responsible for this regulation. In the latest studies, it was indicated that epigenetic modifications targeting the TERT promoter distal region could modulate the binding of TERT repressors and thus telomerase activity (Azouz et al. 2010) . Additionally, TERT expression was found to be regulated by DNA methylation and histone H3-K9 modifications, which was consequently affecting the ability of c-Myc binding in the E-box 1 site in the TERT promoter (Ge et al. 2010) . Interestingly, c-Myc siRNA down-regulation was demonstrated to significantly inhibit TERT expression. Thus, TERT was finally suggested to be regulated by a combination of epigenetic mechanisms (DNA methylation and histone modifications) and by the transcription factors, but in a tissue-specific manner. Additionally activation of telomerase resulting from deregulated TERT expression was shown as a key event during high-risk human papillomavirus (hrHPV)-induced cervical carcinogenesis (de Wilde et al. 2010 ). Thus, the study of TERT promoter methylation at the repressive regions may provide an attractive biomarker for early detection of cervical cancer. Not only factors binding to core promoter have transcriptional influence on TERT expression. Ubiquitously expressed 11 zinc finger nuclear phosphoprotein (CTCF) can inhibit gene transcription by binding to GC-rich sites downstream of the transcriptional start site (Klenova et al. 1993) . ChIP assays indicated that CTCF bound in vivo to the first exon of TERT only in telomerase negative cells (Renaud et al. 2005) . Further examinations revealed that CTCF bound only to the unmethylated CTCF-binding site. Moreover, it was shown that in several cell lines and tumor tissues the CpGs in this region were methylated. Hence, it was suggested that methylation of TERT in tumor cells might be the mechanism preventing CTCF binding and in consequence, allowing TERT gene transcription (Renaud et al. 2007) . Further studies of TERT methylation status revealed that in B cells, some T cell lymphomas, and non-neoplastic lymph nodes, the TERT promoter is unmethylated (Bougel et al. 2010) . Binding sites for the B cell-specific transcription factor PAX5 were identified downstream of the ATG translational start site through EMSA and ChIP experiments. ChIP assays indicated that the transcriptional activation of TERT by PAX5 does not involve repression of CTCF binding. In a B cell lymphoma cell line, siRNA-induced knockdown of PAX5 expression repressed TERT transcription. Moreover, ectopic expression of PAX5 in a telomerase-negative normal fibroblast cell line was found to be sufficient to activate TERT expression. These data show that activation of TERT in telomerase-positive B cells is due to a methylation-independent mechanism in which PAX5 plays an important role. A methylation independent mechanism of TERT regulation was also demonstrated in telomerase-positive B cells. In these cells, TERT is a novel target of PAX5, which is essential for B cell development and function suggesting PAX5 to participate in cellular mechanisms underlying cell immortality by up-regulating TERT gene expression (Bougel et al. 2010) .
Multiple studies of bioactive components mediating epigenetic modifications associated with the induction of tumor suppressor genes such as p21(WAF1/CIP1) and inhibition of tumor promoting genes such as the human telomerase reverse transcriptase during tumorigenesis processes are carried out and (Nittis et al. 2008; Kyo et al. 2008; Patel and Shervington 2009; Meeran et al. 2010a) give great promise for novel epigenetic approaches to cancer prevention and therapy. Especially since recent studies indicate that telomerase is positively regulated through methylation and its elimination enhances chemotherapy. These observations suggest that suppression of telomerase in combination with O6-methylguanine-DNA methyltransferase (MGMT) may have additional anti-proliferative and anti-apoptotic effects, which may lead to increased patient survival rates (Patel and Shervington 2009) . Even if there are a lot of TFs engaged in telomerase expression regulation, none of them clearly account for the cancer specificity of TERT expression. The chromatin structure via the DNA methylation or modulation of nucleosome histones has recently been suggested to be important for regulation of the TERT promoter. DNA unmethylation or histone methylation around the transcription start site of the TERT promoter triggers the recruitment of histone acetyltransferase (HAT) activity, allowing TERT transcription. These facts encourage scientists to investigate the regulatory mechanisms in the context of cancer diagnostics and therapeutics . On the other hand the telomeres can be also rebuilt on the way of the ALT mechanism that is surprisingly more prevalent in tumors arising from tissues of mesenchymal origin than in those of epithelial origin (Nittis et al. 2008) . This observation raises the possibility that telomerase-positive tumors undergoing anti-telomerase therapies might escape by activating the ALT pathway. For these reasons, delineating the ALT mechanism is critical for our understanding of the tumorigenic process and the development of ALT-specific anti-neoplastic therapies. Recent studies have demonstrated that epigenetic modifications at telomeres have a profound effect on telomere length and may also be linked to the ALT mechanism. Although mammalian telomeres do not contain CpG sequences, and are thus not methylated, the subtelomeric regions can be methylated. Thus, changes in either histone modifications at the telomeres or DNA methylation patterns at the subtelomeres are associated with telomere length deregulation (García-Cao et al. 2004; Nittis et al. 2008) .
There is some good news about controlling the TERT expression regulation within some natural compounds, e.g., ATRA (all-trans retinoic acid) was shown to have significant effect on the morphology and proliferation rate of the SK-BR-3 cells (Phipps et al. 2009 ). It was also revealed to decrease the ability of these cancer cells to grow independently and lower telomerase activity that was associated with a rapid decrease in histone H3-lysine 9 acetylation (H3-K9-Ac) of the TERT promoter. Further ATRA treatment was shown to induce apoptosis in estrogen receptor-negative breast cancer cells (Phipps et al. 2009 ).
Another telomerase inhibiting natural compound sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables, is a common dietary component that has histone deacetylase inhibition activity and significant potential in cancer prevention. The mechanism of action is supposed to act through decrease of DNA methyltransferases (DNMTs), especially DNMT1 and DNMT3a, suggesting that SFN may repress TERT by impacting epigenetic pathways (Meeran et al. 2010b) . Similarly, trichostatin A (TSA), an inhibitor of histone deacetylase, is a well-known antitumor agent that effectively and selectively induces tumor growth arrest and apoptosis. Recently, it was reported that TERT is one of the primary targets for TSA-induced apoptosis in HCT116 colon cancer cells. TSA was found to induce the demethylation of site-specific CpGs on the promoter of TERT, which was caused by down-regulation of DNA methyltransferase 1 (DNMT1) followed by demethylation of a CTCF binding site on the TERT promoter and finally repression of TERT via recruitment of CTCF to the promoter (Choi et al. 2010) . Thus, the TERT promoter regions methylation status appears to become another prognostic marker while its regulation seems to be a promising strategy against telomerase activity in the context of both carcinogenesis and cancer treatment.
Telomere binding proteins
Factors that affect the regulation of telomerase gene expression could be potentially good solutions for anti-cancer therapy. Inactivation of enzymes may cause shortening of telomeres and eventually the induction of cellular senescence and (or) apoptosis. On the other hand, telomere loss is a gradual process and there is a lag between the time telomerase is inhibited and the time telomeres sufficiently shorten to disrupt the capping function. Hence, telomere accessibility is also the potential issue that can be taken under consideration to enhance effectiveness of therapy (Seimiya 2006) . Shelterin, a complex composed of 6 proteins, is responsible for telomere protection, facilitation of the replication process, and telomerase access. TRF1 and TRF2 bind the doublestranded telomere. POT1 and TPP1 are OB-fold (oligonucleotide-or oligosaccharide-binding) containing proteins associated with the single-stranded overhang. RAP1 binds TRF2, and TIN2 is a central component of the complex interacting with TRF1, TRF2, and TPP1 (Artandi and DePinho 2010) . In addition, proteins that bind along the telomere are part of a negative feedback loop that regulates telomere length and are involved in an indirect mechanism of telomerase activity regulation (Wojtyla et al. 2011) . The TRF1 can be poly(ADP-ribosyl)ated by tankyrase 1 (TRF1-interacting ankyrin-related ADP-ribose polymerase 1), and this modification blocks the ability of TRF1 to bind telomeric DNA in vitro (Smith et al. 1998) . Furthermore, in intact human cells, tankyrase 1 releases TRF1 from telomeres in a PARP activity-dependent manner (Smith and de Lange 1999; Cook et al. 2002) . The released TRF1 is rapidly ubiquitinated and subjected to proteasomal degradation (Chang et al. 2003) . Tankyrase 1 works as a positive regulator for telomere elongation by telomerase, hence inhibition of tankyrases, which enhance telomerase access to telomeres, may indirectly induce cancer cell senescence by abrogating telomerase activity (Seimiya 2006) . Thus, all subunits of the complex contribute to telomerase stabilization/destabilization and can be considered as targets to modulate telomerase expression and activity.
Other factors
In aadditionally to methylation, other epigenetic factors also contribute to telomerase expression and other genes regulation including chromatin structure (Stein et al. 2000) , histone acetylation, and deacetylation of the TERT promoter (Xu et al. 2001 ) that may mediate Myc/Max and Mad/Max regulation via E-boxes (Takakura et al. 2001) . Among all the factors regulating telomerase expression and activity, a few polymorphisms and mutations were also identified. As reported, in leukocytes from patients with mutations in TERT, short telomeres and low telomerase enzymatic activity was demonstrated (Yamaguchi et al. 2005) . Additional synonymous, single-nucleotide polymorphisms identified in TERT resulted in susceptibility to dyskeratosis congenita and haploinsufficiency (Armanios et al. 2005 (Armanios et al. , 2007 or adult-onset idiopathic pulmonary fibrosis (IPF) (Tsakiri et al. 2007; Alder et al. 2008 ) and coronary artery disease (Matsubara et al. 2006) . Heterozygous deletion of TERT were also described as risk factors in cri-du-chat syndrome (Zhang et al. 2003) .
Mutations in the TERC gene cause short telomeres in congenital aplastic anemia of dyskeratosis congenita (DKC) and in some cases of apparently acquired aplastic anemia (Vulliamy et al. 2001; Comolli et al. 2002; Fogarty et al. 2003; Theimer et al. 2003; Vulliamy et al. 2004; Goldman et al. 2005; Yamaguchi et al. 2005) . Mutations can also cause aplastic anemia (Vulliamy et al. 2001 ) and susceptibility to pulmonary fibrosis (Alder et al. 2008; Armanios et al. 2007 ).
Telomerase as a target in anti-cancer therapy
According to the common conviction, lack of telomerase expression/activity would limit the growth of tumors by causing continually dividing cells to lose their telomeres and die before starting to spread. This is why telomerase inhibitors seem to be promising factors eliminating cancer cells. Additionally, telomerase catalytic subunit expression shows correlations with multidrug resistance, i.e., MDR-and apoptosisrelated genes and is of prognostic significance (Wang et al. 1999; Siva et al. 2001) . The contribution of telomerase to multidrug resistance was suggested to result from increased chromosome stability and a strong expression of both ABCB1 (MDR1) and ABCC (MRP) genes (Kuranaga et al. 2001) . As reported by Ji et al. (2006) , TR antisense oligonucleotides could down-regulate telomerase activity, increase radiation induced DNA damage, and reduce the subsequent repair. Furthermore, it could inhibit the proliferation and increase radiosensitivity, however, without telomere shortening. Similarly, Cerone et al. (2006) demonstrated that mutated TR coding subunit resulted in an increased sensitivity of breast cancer cells to anti-cancer drugs in cells with different initial telomere lengths and mechanisms of telomere maintenance and without requiring overall telomere shortening. Furthermore, Massard et al. (2006) demonstrated that TERT inhibition may constitute a promising strategy for facilitating the induction of the mitochondrial pathway of apoptosis. Additionally, it was reported that the effect of doxorubicin was potentiated by the RNA interference directed against telomerase subunits (Dong et al. 2009 ). Thus, it was concluded that telomerase targeting associated with increased sensitization and efficacy for triggering senescence and (or) apoptosis in cancer cells is possible and highly desired (Poynter et al. 2009 ).
Summary and conclusions
Cancer therapy is still a challenge due to an increased number of risk factors, including stress, age, senescence, and chemical industry development. The tricky thing about cancer cells is that they come directly from our cells showing only minor differences that distinguish them from other noncancer cells. One of the unique features of cancer cells is telomerase activity/expression, thus becoming an attractive target for therapy. This quite common marker is present in over 90% of cancer cells; however, the latest reports show the enzyme activity is also in stem cells and in some somatic cells. Despite this, the study of this cancer-related marker in the context of its regulation becomes of topical interest for medical pharmacy and molecular biology. The enzymatic complex is composed of different subunits that are regulated in a tissue-specific way. This multistep mechanism controls the cell cycle division, survival, mitochondrial activity (Natarajan et al. 2004; Ahmed et al. 2008) , and drug resistance (Smith et al. 2009 ). As revealed in many studies, the key regulatory subunits of the telomerase are probably TERT or TR. However, the enzyme regulation is a complex process, still not completely understood but due to significant meaning, it is very interesting. A lot of efforts were taken to identify new compounds that would be able to modify telomerase expression and activity. A very promising direction of the studies is the quadruplex stabilizers (Rubis et al. 2009 ) and siRNA (George et al. 2009 ) or antisense oligonucleotides technology (Noreen et al. 2009 ), which are being intensively studied as potential tools in anti-cancer, telomerase-related therapy. Noteworthy, the RNA interference and antisense nucleotide technology directed against telomerase subunits coding genes are already applied in the second and even third clinic phase study (GRN163L,GRNVAC1, and GRNVAC2; Geron, USA). It is supposed to use these methods as an adjuvant therapy. An understanding of telomerase activity may then bring new insight into many serious clinical problems at the level of cell biology that we have to face in ageing society.
Cancer cells commonly have a high rate of telomere loss, even when expressing telomerase, resulting from chromosome instability, double-strand breaks, and tumor cell progression (Murnane 2010) . Hence, the thing is how to increase the telomeres loss rate and how to do it specifically. Thus, the more we know about the regulation, the more possible targets appear and the development of novel approaches for anti-cancer therapy will also arise. The only thing we must remember is that all the therapies should be directed specifically, especially since telomeres and telomerase are main components of the stem cell. Moreover, they also contribute to stem cell control, providing, respectively, on one hand a way to regenerate human body and delay aging (Sahin and Depinho 2010) 
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